Haemonetics: Re-Rating Complete, Time To Cash In (NYSE:HAE)

Group 1 - The article discusses the investment opportunities and risks associated with Haemonetics (HAE), particularly after a significant decline in its share price despite the company maintaining its full-year guidance [1]. - The investment group "Value In Corporate Events" focuses on identifying actionable ideas from major corporate events such as earnings reports, mergers and acquisitions, and IPOs, providing coverage of approximately 10 major events each month [1]. - The author emphasizes the importance of tracking companies through catalytic events to uncover potential investment opportunities [1]. Group 2 - The article indicates a shift in the author's position regarding HAE, suggesting a move towards selling a long position [3].